Astellas Venture Management

Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating disease-driving cells. Utilizing its unique cytotoxicity-targeting chimera platform, the company focuses on creating oncology therapeutics that address not only cancer but also inflammatory and autoimmune diseases. By targeting and eliminating these harmful cells, Solu Therapeutics seeks to enhance treatment efficacy and reduce the associated risks in oncology, ultimately aiming to improve patient outcomes in various medical conditions.

SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.

PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, established in 2014. The company specializes in identifying new druggable targets for cancer and other unmet medical needs through its innovative Site-Seeker platform. This platform systematically reveals cryptic druggable sites within the human genome and connects them to therapeutic functions in a live-cell context. By utilizing functionally validated protein fragments, PhoreMost informs the design of small molecule drugs that can be developed into targeted therapies. The company collaborates with a global network of academic and industrial partners to efficiently advance novel therapies to market, aiming to reduce costs and improve accessibility for patients.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

Shinobi Therapeutics is a biotechnology company dedicated to developing innovative cell therapies that utilize hypoimmune CD8αβ induced pluripotent stem cells (iPS-T cells) to enhance cancer treatment and address other diseases. The company's advanced immune evasion technology aims to improve the effectiveness and accessibility of these therapies, ultimately reducing costs and enhancing patient outcomes. By focusing on durable responses and the potential for redosing, Shinobi Therapeutics strives to provide the healthcare industry with comprehensive immune therapies that can address a range of diseases, including cancer and genetic disorders.

Mogrify is a biotechnology company that has created a proprietary suite of platform technologies aimed at advancing cellular reprogramming and maintaining cell identity. Developed over 12 years through an international research collaboration, its platforms, MOGRIFY and epiMOGRIFY, leverage big data, next-generation sequencing, and gene regulatory networks to predict the necessary transcription and growth factors for generating any desired human cell type from various sources. Mogrify's technology can enhance existing stem-cell programming methods or facilitate direct transdifferentiation between mature cell types, thereby generating functional cells for therapeutic applications. The company focuses on developing innovative in vivo reprogramming therapies targeted at conditions in ophthalmology, otology, metabolic diseases, and other degenerative disorders. Positioned to tap into a regenerative medicine market projected to reach $150 billion by 2028, Mogrify pursues commercialization through therapy development, co-development partnerships, and the application of its platforms in diverse therapeutic and non-therapeutic areas.

Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating disease-driving cells. Utilizing its unique cytotoxicity-targeting chimera platform, the company focuses on creating oncology therapeutics that address not only cancer but also inflammatory and autoimmune diseases. By targeting and eliminating these harmful cells, Solu Therapeutics seeks to enhance treatment efficacy and reduce the associated risks in oncology, ultimately aiming to improve patient outcomes in various medical conditions.

Avilar Therapeutics is a biopharmaceutical company dedicated to the discovery and development of innovative extracellular protein degraders, representing a new approach in targeted protein degradation. The company has created an integrated discovery platform aimed at extending protein degradation beyond intracellular proteins. Avilar's novel degraders function by binding to disease-causing proteins in circulation and transporting them to the hepatocyte endolysosome, where these unwanted proteins are degraded. This mechanism offers potential therapeutic solutions for the treatment of serious diseases, positioning Avilar Therapeutics at the forefront of advancing medical treatments through targeted protein management.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

Casma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy. Founded in 2017, the company aims to enhance autophagy to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing significant medical challenges. Casma Therapeutics is advancing preclinical programs targeting various conditions, including muscle disorders, liver disease, inflammatory disorders, and neurodegenerative diseases. By harnessing and manipulating the autophagy system, the company seeks to arrest or reverse disease progression, ultimately enabling physicians to meet unmet medical needs and provide effective treatments for patients with serious health issues.

DEM BioPharma is an immuno-oncology company focused on developing innovative therapies to combat cancer by harnessing the innate immune system. The company is pioneering a platform dedicated to creating next-generation macrophage immunotherapies, which aim to activate macrophages and immune phagocytes to effectively target and eliminate tumors. By researching and targeting specific signals on both cancer cells and macrophages, DEM BioPharma seeks to provide healthcare researchers with advanced treatment options that enhance the body's ability to fight cancer.

Carbon Biosciences is a biotechnology company focused on developing genetic medicines aimed at treating serious diseases. The company utilizes a proprietary platform based on novel parvoviruses, which have been optimized through natural selection to effectively target specific tissues and deliver larger therapeutic cargoes. This technology is designed to minimize neutralizing immunity, allowing for potential re-dosing. Carbon Biosciences specifically targets lung tissues and has demonstrated success in preclinical models, including those for cystic fibrosis. Through its industrial-scale viral production platforms, the company aims to extend the reach of gene therapies, providing innovative solutions for previously challenging medical conditions.

Turn.bio is a biotechnology company focused on developing innovative therapies aimed at reversing aging and age-related diseases. Leveraging a patented mRNA platform technology known as ERA, along with a specialized delivery system called eTurna, the company targets the epigenome to restore optimal gene expression. By designing tailored therapies, Turn.bio addresses a range of conditions, including immune-related diseases such as cancer, dermatological issues, and ailments in ophthalmology, osteoarthritis, and the muscular system. The company's approach involves inducing the body to heal itself by instructing specific cells to combat disease and repair damaged tissue, thereby reprogramming cellular functions to enhance health and longevity.

Toregem Biopharma is a startup based in Kyoto, Japan, affiliated with Kyoto University, focused on developing innovative treatments for congenital adentia and other dental health issues. The company specializes in therapeutic agents aimed at dental regeneration, specifically designed to restore teeth using patients' own tissues. By researching and advancing dental regenerative medicine, Toregem Biopharma seeks to provide solutions for individuals who have lost their teeth due to conditions such as tooth decay or periodontal disease, ultimately helping them regain a healthy and functional smile.

Mogrify is a biotechnology company that has created a proprietary suite of platform technologies aimed at advancing cellular reprogramming and maintaining cell identity. Developed over 12 years through an international research collaboration, its platforms, MOGRIFY and epiMOGRIFY, leverage big data, next-generation sequencing, and gene regulatory networks to predict the necessary transcription and growth factors for generating any desired human cell type from various sources. Mogrify's technology can enhance existing stem-cell programming methods or facilitate direct transdifferentiation between mature cell types, thereby generating functional cells for therapeutic applications. The company focuses on developing innovative in vivo reprogramming therapies targeted at conditions in ophthalmology, otology, metabolic diseases, and other degenerative disorders. Positioned to tap into a regenerative medicine market projected to reach $150 billion by 2028, Mogrify pursues commercialization through therapy development, co-development partnerships, and the application of its platforms in diverse therapeutic and non-therapeutic areas.

PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, established in 2014. The company specializes in identifying new druggable targets for cancer and other unmet medical needs through its innovative Site-Seeker platform. This platform systematically reveals cryptic druggable sites within the human genome and connects them to therapeutic functions in a live-cell context. By utilizing functionally validated protein fragments, PhoreMost informs the design of small molecule drugs that can be developed into targeted therapies. The company collaborates with a global network of academic and industrial partners to efficiently advance novel therapies to market, aiming to reduce costs and improve accessibility for patients.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

Orna Therapeutics, founded in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts, is a biotechnology company specializing in the development of fully engineered circular RNA therapeutics. The company's proprietary platform combines innovative technology to create circular RNAs that drive protein expression, coupled with validated delivery solutions. This approach aims to simplify production, enhance formula stability, and improve protein expression for treating various diseases.

Jupiter Therapeutics is a biotechnology company specializing in the development of cell-membrane-based therapeutics. It employs cell engineering techniques to create customized vesicles aimed at advancing immuno-oncology and gene therapy. By leveraging a synthetic biology approach, Jupiter Therapeutics facilitates the rapid design and synthesis of a diverse pipeline of therapeutic assets that address critical areas such as cancer and autoimmunity. The company allows medical researchers to utilize insights from cell-membrane studies to enhance the effectiveness of CAR T-cells and bi-specific antibodies, thereby contributing to innovative treatments in the biotherapeutics field.

Keyhole Therapeutics is a discovery stage drug company specializing in immunotherapies for cancer and autoimmune diseases. Keyhole's first program, a small molecule inhibitor of exosome release being investigated for promotion of immune-driven tumor destruction in cancer patients resistant to current immune checkpoint inhibitors, is at the hit-to-lead stage. Future programs will include additional inhibitors of exosome release, and novel exosome-related therapeutic opportunities for cellular cancer vaccines and for targeted suppression of autoreactive T cells. Keyhole Therapeutics is seeking bold, accomplished, and innovative scientists to join them in pioneering the next wave of immunotherapeutics.

Catamaran Bio, Inc. is a biotechnology company focused on developing allogeneic CAR-NK immune cell therapies for the treatment of solid tumors and other cancers. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf CAR-NK cell therapy products. By leveraging genetic engineering, Catamaran Bio aims to address significant unmet medical needs in cancer treatment, providing transformative therapies for patients.

Fukushima SiC Applied Engineering is a manufacturer of silicon carbide semiconductor devices for the medical and industrial fields. Using this SiC device, Fukushima SiC Applied Engineering Research Institute has the technology to design and manufacture circuits that handle high voltages and currents ranging from 10 KV to several hundred kV and 10 A to 1000 A. The company commercializes a circuit that uses a series resonance circuit to achieve high output and stability.

Trishula Therapeutics is a privately held biotechnology company focused on developing innovative cancer immunotherapies. The company's lead product, TTX-030, is a first-in-class anti-CD39 antibody developed in collaboration with AbbVie. TTX-030 works by inhibiting CD39, an enzyme that converts ATP to AMP, thereby preventing the formation of immune-suppressive extracellular adenosine in the tumor microenvironment. This mechanism helps maintain elevated levels of immune-activating extracellular ATP, which is essential for stimulating dendritic and myeloid-derived cells involved in both innate and adaptive immunity. Currently, TTX-030 is undergoing phase 1/1b clinical trials as a monotherapy and in combination with anti-PD-1 agents and standard chemotherapy for adults with advanced cancer, aiming to enhance anti-tumor immune responses and improve treatment outcomes for cancer patients.

TScan Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing T cell receptor (TCR) engineered T cell therapies for cancer treatment. Its primary focus is on liquid tumors, with lead therapy candidates TSC-100 and TSC-101 aimed at addressing hematologic malignancies by targeting residual leukemia and preventing relapse following hematopoietic stem cell transplantation. In addition to its liquid tumor programs, TScan is advancing multiplexed TCR-T therapy candidates to tackle various solid tumors. The company employs a unique platform that identifies previously uncharacterized shared T cell antigens and assesses off-target TCR interactions, which supports the creation of TCR-T therapies with reduced off-target effects. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics aims to transform cancer treatment through innovative T cell therapies.

Heartseed Inc. is a Tokyo-based biotechnology company founded in 2015, focused on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company's mission is to advance treatments for heart disease through regenerative medicine, specifically targeting advanced heart failure with iPS cell-derived cardiomyocyte replacement therapy. Heartseed aims to enable the clinical application of its innovative therapies to improve outcomes for patients suffering from heart conditions.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Redona Therapeutics is a biotechnology company focused on developing RNA-based therapies aimed at treating cancer and other human diseases. The company specializes in the modulation of functional non-coding RNA (ncRNA) through the use of small molecules that target ncRNA modulating proteins (RMPs). By researching short non-coding RNAs, Redona Therapeutics creates drugs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay. This innovative approach enables the modulation of microRNAs (miRNAs) that are directly involved in cancer initiation, progression, and metastasis, offering potential new avenues for treatment in oncology and beyond.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Heartseed Inc. is a Tokyo-based biotechnology company founded in 2015, focused on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company's mission is to advance treatments for heart disease through regenerative medicine, specifically targeting advanced heart failure with iPS cell-derived cardiomyocyte replacement therapy. Heartseed aims to enable the clinical application of its innovative therapies to improve outcomes for patients suffering from heart conditions.

eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that specializes in the development of selective translation regulators for the treatment of cancer and other serious diseases. Founded in 2012, the company is pioneering a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). These drug candidates specifically target the eIF4F complex and its associated kinase, MNK 1/2, which play critical roles in protein synthesis and are linked to prominent cancer signaling pathways such as PI3K-AKT and RAS-MEK. eFFECTOR's products aim to inhibit pathways that drive tumor growth, survival, and immune evasion by regulating the expression of oncoproteins and immunosuppressive proteins. The lead candidate, tomivosertib, is currently being evaluated in a Phase 2b trial for non-small cell lung cancer in combination with pembrolizumab. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation in a Phase 1/2 trial, with further expansion cohorts anticipated. The company also collaborates with Pfizer to advance inhibitors targeting eIF4E.

J-BEAM develops, manufactures, and sells products that apply silicon carbide semiconductors. Utilizing SiC semiconductor technology, it has developed a treatment device for boron neutron capture therapy (BNCT) and is working toward its practical application.

Oncorus, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead product candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently undergoing Phase I clinical trials to assess its efficacy against various cancers. In addition to ONCR-177, Oncorus is advancing its ONCR-GBM program aimed at treating brain cancer, along with synthetic viral immunotherapies derived from Coxsackievirus A21 and Seneca Valley Virus. The company has established a clinical trial collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s KEYTRUDA immunotherapy. Founded in 2015, Oncorus is committed to improving patient outcomes and has pledged to contribute a portion of its product sales to support cancer research and care in developing regions.

Trieza Therapeutics is a biotechnology company focused on developing immunomodulatory oncolytic viruses for cancer treatment. Established as a spin-out from Potenza Therapeutics, the company is dedicated to creating a diverse portfolio of pre-clinical candidates. Trieza's therapeutics aim to stimulate robust anti-tumor immune responses by integrating selective tumor lysis with the rapid expression of engineered transgenes that encode immunomodulatory agents. This innovative approach enables the potential to enhance the efficacy of immune-stimulants, checkpoint inhibitors, and ligands for co-inhibitory receptors, ultimately offering new therapeutic options for cancer patients.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Tizona Therapeutics, Inc. is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. Founded in 2014 and based in South San Francisco, California, the company is engaged in creating innovative treatments that target immunosuppressive cells and mechanisms within the tumor microenvironment. Its product pipeline includes an Anti-CCR4 antibody for cancer therapy, as well as IL-35 antagonists and agonists aimed at addressing both cancer and autoimmune conditions. Tizona is also collaborating with its scientific founders to investigate the role of regulatory T cells in various tumors, enhancing the understanding of their contribution to immunosuppression. This research aims to differentiate the company’s approach and improve patient outcomes by facilitating complete and lasting remissions.

Tizona Therapeutics, Inc. is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. Founded in 2014 and based in South San Francisco, California, the company is engaged in creating innovative treatments that target immunosuppressive cells and mechanisms within the tumor microenvironment. Its product pipeline includes an Anti-CCR4 antibody for cancer therapy, as well as IL-35 antagonists and agonists aimed at addressing both cancer and autoimmune conditions. Tizona is also collaborating with its scientific founders to investigate the role of regulatory T cells in various tumors, enhancing the understanding of their contribution to immunosuppression. This research aims to differentiate the company’s approach and improve patient outcomes by facilitating complete and lasting remissions.

eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that specializes in the development of selective translation regulators for the treatment of cancer and other serious diseases. Founded in 2012, the company is pioneering a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). These drug candidates specifically target the eIF4F complex and its associated kinase, MNK 1/2, which play critical roles in protein synthesis and are linked to prominent cancer signaling pathways such as PI3K-AKT and RAS-MEK. eFFECTOR's products aim to inhibit pathways that drive tumor growth, survival, and immune evasion by regulating the expression of oncoproteins and immunosuppressive proteins. The lead candidate, tomivosertib, is currently being evaluated in a Phase 2b trial for non-small cell lung cancer in combination with pembrolizumab. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation in a Phase 1/2 trial, with further expansion cohorts anticipated. The company also collaborates with Pfizer to advance inhibitors targeting eIF4E.

Crescendo Biologics Limited is a clinical-stage biotechnology company based in Cambridge, United Kingdom, specializing in the development of innovative therapies for oncology and dermatology. The company focuses on creating multi-specific immune-oncology modulators and Humabody Drug Conjugates using its proprietary transgenic mouse platform. This technology allows for the in vivo maturation of human VH domains, optimizing their affinity and biophysical properties for therapeutic use. Crescendo Biologics aims to address critical challenges in generating high-affinity, soluble human VH antibody fragments, which are recognized for their potential as effective therapeutics. By leveraging its advanced platforms, the company is engaged in the product development of in-house targets as well as collaborations with other organizations to enhance the efficacy of cancer treatments. Founded in 2007 and originally known as Translocus Limited, Crescendo Biologics has established itself as a leader in the field of next-generation antibody therapeutics.

Viamet Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies that target metalloenzymes, employing its proprietary Metallophile Technology. This technology leverages expertise in bioinorganic chemistry to identify and optimize small molecule compounds that inhibit validated metalloenzymes, which are crucial for various therapeutic applications. Viamet focuses on creating best-in-class treatments for serious conditions, including invasive fungal infections, cancer, cardiovascular diseases, and orphan diseases, by enhancing the therapeutic potential of existing metalloenzyme inhibitors. Through its unique approach, Viamet aims to deliver novel, patentable therapeutic agents that effectively disrupt the cellular utilization of essential metal ions such as zinc and iron.

Raze Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative oncology therapeutics that target essential metabolic pathways in cancer cells. By leveraging new biological insights into the reprogramming of metabolism that allows tumors to grow and survive, Raze is advancing a pipeline of therapies that specifically target one-carbon metabolism. This proprietary platform aims to facilitate quicker treatment initiation for patients and enhance the likelihood of successful outcomes.

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of a novel class of medicines known as Bicycles. These are synthetic short peptides designed to form two loops that stabilize their structure. The company's lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) currently undergoing Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also a BTC in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies targeting Nectin-4. Additionally, Bicycle is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to address therapeutic areas such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics was incorporated in 2009 and aims to address significant unmet medical needs in oncology and beyond.

Crescendo Biologics Limited is a clinical-stage biotechnology company based in Cambridge, United Kingdom, specializing in the development of innovative therapies for oncology and dermatology. The company focuses on creating multi-specific immune-oncology modulators and Humabody Drug Conjugates using its proprietary transgenic mouse platform. This technology allows for the in vivo maturation of human VH domains, optimizing their affinity and biophysical properties for therapeutic use. Crescendo Biologics aims to address critical challenges in generating high-affinity, soluble human VH antibody fragments, which are recognized for their potential as effective therapeutics. By leveraging its advanced platforms, the company is engaged in the product development of in-house targets as well as collaborations with other organizations to enhance the efficacy of cancer treatments. Founded in 2007 and originally known as Translocus Limited, Crescendo Biologics has established itself as a leader in the field of next-generation antibody therapeutics.

Crescendo Biologics Limited is a clinical-stage biotechnology company based in Cambridge, United Kingdom, specializing in the development of innovative therapies for oncology and dermatology. The company focuses on creating multi-specific immune-oncology modulators and Humabody Drug Conjugates using its proprietary transgenic mouse platform. This technology allows for the in vivo maturation of human VH domains, optimizing their affinity and biophysical properties for therapeutic use. Crescendo Biologics aims to address critical challenges in generating high-affinity, soluble human VH antibody fragments, which are recognized for their potential as effective therapeutics. By leveraging its advanced platforms, the company is engaged in the product development of in-house targets as well as collaborations with other organizations to enhance the efficacy of cancer treatments. Founded in 2007 and originally known as Translocus Limited, Crescendo Biologics has established itself as a leader in the field of next-generation antibody therapeutics.

eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that specializes in the development of selective translation regulators for the treatment of cancer and other serious diseases. Founded in 2012, the company is pioneering a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). These drug candidates specifically target the eIF4F complex and its associated kinase, MNK 1/2, which play critical roles in protein synthesis and are linked to prominent cancer signaling pathways such as PI3K-AKT and RAS-MEK. eFFECTOR's products aim to inhibit pathways that drive tumor growth, survival, and immune evasion by regulating the expression of oncoproteins and immunosuppressive proteins. The lead candidate, tomivosertib, is currently being evaluated in a Phase 2b trial for non-small cell lung cancer in combination with pembrolizumab. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation in a Phase 1/2 trial, with further expansion cohorts anticipated. The company also collaborates with Pfizer to advance inhibitors targeting eIF4E.

DecImmune Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative peptides and antibodies to address acute tissue-damaging inflammation associated with conditions such as myocardial infarction, burns, and vascular injury. The company aims to create therapeutics that treat second-degree burns and prevent reperfusion injury in transplant patients. It has made significant advancements in monoclonal antibodies targeting innate pathways to mitigate tissue damage and preserve organ function, particularly in the context of vascular inflammatory diseases. Founded in 2001 and originally named Natural Antibodies, Inc., DecImmune Therapeutics has since established itself as a key player in the field of inflammation and autoimmunity.

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of a novel class of medicines known as Bicycles. These are synthetic short peptides designed to form two loops that stabilize their structure. The company's lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) currently undergoing Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also a BTC in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies targeting Nectin-4. Additionally, Bicycle is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to address therapeutic areas such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics was incorporated in 2009 and aims to address significant unmet medical needs in oncology and beyond.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments aimed at improving the survival and quality of life for cancer patients. Based in Needham, Massachusetts, Verastem markets COPIKTRA (duvelisib), an oral medication indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after multiple prior therapies. In addition to this approved therapy, the company is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, which is being studied in combination with immunotherapies for various cancers, including pancreatic and ovarian cancers, as well as non-small cell lung cancer. Verastem's research emphasizes inhibiting critical signaling pathways that promote cancer cell survival and tumor growth, particularly those associated with the RAS/MAPK pathway. The company has formed collaborative agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its development efforts. Founded in 2010, Verastem continues to focus on late-stage development of its anticancer agents.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

PanOptica, Inc. is a biotechnology company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases caused by abnormal or leaky blood vessels. Founded in 2009 and headquartered in Mount Arlington, New Jersey, PanOptica is advancing its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist, which shows potential as a topical treatment for conditions such as wet age-related macular degeneration and diabetic retinopathy. The company aims to address significant unmet needs in ophthalmology by offering new therapeutic options that can improve vision and enhance the quality of life for patients suffering from debilitating eye diseases. By collaborating with pharmaceutical companies, PanOptica seeks to license and develop innovative treatments that may include enhancements to existing therapies or novel solutions for previously untreatable conditions.

DecImmune Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative peptides and antibodies to address acute tissue-damaging inflammation associated with conditions such as myocardial infarction, burns, and vascular injury. The company aims to create therapeutics that treat second-degree burns and prevent reperfusion injury in transplant patients. It has made significant advancements in monoclonal antibodies targeting innate pathways to mitigate tissue damage and preserve organ function, particularly in the context of vascular inflammatory diseases. Founded in 2001 and originally named Natural Antibodies, Inc., DecImmune Therapeutics has since established itself as a key player in the field of inflammation and autoimmunity.

Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery, development, and commercialization of innovative epigenetic medicines for cancer and other serious diseases. Founded in 2007, the company has developed Tazemetostat, an approved treatment for metastatic or locally advanced epithelioid sarcoma, and is exploring its use in various combinations for other malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition to Tazemetostat, Epizyme is advancing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, and inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several prominent organizations in the pharmaceutical sector to enhance its research and development efforts.

Viamet Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies that target metalloenzymes, employing its proprietary Metallophile Technology. This technology leverages expertise in bioinorganic chemistry to identify and optimize small molecule compounds that inhibit validated metalloenzymes, which are crucial for various therapeutic applications. Viamet focuses on creating best-in-class treatments for serious conditions, including invasive fungal infections, cancer, cardiovascular diseases, and orphan diseases, by enhancing the therapeutic potential of existing metalloenzyme inhibitors. Through its unique approach, Viamet aims to deliver novel, patentable therapeutic agents that effectively disrupt the cellular utilization of essential metal ions such as zinc and iron.

Intradigm is a private biotechnology company specializing in the development of systematic RNA interference (RNAi) therapeutics aimed at treating serious diseases, particularly in the field of oncology. The company leverages its expertise in drug development and delivery to create an innovative RNAi platform. Central to its approach is the proprietary RNAi Nanoplex delivery technology, which allows for the targeted systemic delivery of RNAi therapeutics to specific tissues. Intradigm's portfolio includes a range of siRNA sequences designed to address various oncology and other disease targets, complemented by biodegradable polycationic polymers that enhance the delivery of these therapeutics.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Inimex Pharmaceuticals Inc. is a biopharmaceutical company based in Burnaby, Canada, specializing in the development and commercialization of innate defense regulators (IDRs). These innovative agents are designed to selectively modulate the body's innate immune responses without inducing inflammation. The company's lead product, IMX942, aims to enhance survival rates, mitigate tissue damage, and decrease the risk of bacterial infections. Inimex's IDRs are intended for the treatment of various infections and conditions related to tissue injury, including ventilator-associated pneumonia, tracheobronchitis, bacteremia, endocarditis, mucositis, and certain cancers. Founded in 2001, Inimex Pharmaceuticals is focused on advancing its clinical-stage products to improve patient outcomes.

CoMentis, Inc. is a biotechnology company dedicated to the research, discovery, and development of small-molecule drugs aimed at treating neurovascular diseases, particularly Alzheimer's disease and schizophrenia. The company is focused on creating nicotinic acetylcholine receptor modulators to address cognitive disorders. Founded in 2004 as Athenagen, Inc., it underwent a name change to CoMentis in February 2007 after merging with Zapaq, Inc., which strengthened its position in the neurovascular disease sector. CoMentis is headquartered in South San Francisco, California.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Lectus Therapeutics Limited is a UK-based pharmaceutical company dedicated to developing first-in-class therapeutics targeting ion channels. Utilising proprietary proteomics technology, Lectus aims to create innovative treatments focused on pain management and urinary bladder disorders.